InsidersTradesSigma
Track the Hoth Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 28 August 2025 (Attribution). Among the most active insiders: Knie Robb. All data is accessible without an account.
Analysts rate Hoth Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Hoth Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for skin diseases. It aims to provide therapeutic solutions to enhance patients' quality of life.